Use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) in patients with resistant hypertension and advanced chronic kidney disease: A case analysis / 中国药学杂志

ABSTRACT

OBJECTIVE: To discuss the efficacy and safety of agiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in patients with resistant hypertension and advanced chronic kidney disease. METHODS: The treatment of resistant hypertension in one patient with chronic kidney disease (stage 4) was analyzed. According to the latest guidelines and clinical trials, actual treatment situation was summarized and analyzed. RESULTS AND CONCLUSION: The efficacy and safety of ACEIs or ARBs in patients with advanced chronic kidney disease and hypertension remain uncertain, thus, cautions should be exercised. It's reasonable to use low dose ARBs for such a young patient, nevertheless, it is emphasised that pharmacists and physicians should regularly and constantly monitor the patients' serum levels of creatinine and potassium and late-onset renal failure resulted from angiotensin blockade in patients on ACEIs/ARBs in a collaborative way.